European Medicines Agency Boosts Focus on Women's Health in Drug Development

The European Medicines Agency (EMA) has unveiled new initiatives designed to better integrate women's health considerations into the entire lifecycle of medicines. These efforts include funding post-authorization studies for drugs used during pregnancy and improving methods for detecting pregnancy-specific safety signals. The EMA also plans to update labeling requirements and strengthen collaboration to address methodological challenges in this area.